Neurogene (NGNE) Amortizatization of Intangibles (2020 - 2026)
Neurogene's (NGNE) quarterly Amortizatization of Intangibles came in at $7000.0 in Q1 2026, down 46.15% YoY from $13000.0 in Q1 2025, and down 98.6% on a QoQ basis from $500000.0 in Q4 2025.
Analysis
Neurogene (NGNE) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Neurogene (NGNE) has 5 years of Amortizatization of Intangibles data on file, last reported at $7000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 46.15% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $531000.0 (down 78.08% YoY) and the FY2025 annual result came in at $4.5 million, up 87.52% from the prior year.
- Amortizatization of Intangibles fell to $7000.0 in Q1 2026, from $500000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $2.4 million in Q4 2024 to a low of -$105000.0 in Q4 2022.
- A 5-year average of $205800.0 and a median of $12000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles slumped 90.74% — and 2024, when it surged 2166.67%.
- Tracing NGNE's Amortizatization of Intangibles over 5 years: stood at -$105000.0 in 2022, then surged by 200.0% to $105000.0 in 2023, then surged by 2166.67% to $2.4 million in 2024, then sank by 78.99% to $500000.0 in 2025, then sank by 98.6% to $7000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $7000.0 (Q1 2026), $500000.0 (Q4 2025), and $12000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | 7,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,000.00 |
| Mar 31, 2026 | 374,000.00 |
| Dec 31, 2025 | 500,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 1.75 Mn |
| Dec 31, 2024 | 959,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | 446,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Dec 31, 2022 | -772,000.00 |
| Sep 30, 2022 | 267,000.00 |
| Jun 30, 2022 | 259,000.00 |
| Mar 31, 2022 | 250,000.00 |
| Dec 31, 2021 | 241,000.00 |
| Sep 30, 2021 | 236,000.00 |